Previous close | 15.68 |
Open | 15.68 |
Bid | 15.70 |
Ask | 16.80 |
Strike | 82.50 |
Expiry date | 2024-08-16 |
Day's range | 15.68 - 15.68 |
Contract range | N/A |
Volume | |
Open interest | 149 |
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study. The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people. Also Read: Gilead’s Aggressive Push Beyond HIV Treatments